• Joanna Thomson

COVID-19 update: 3 bio-pharma giants release clinical trial protocols


With the September deadline set by researchers at the University of Oxford looking like it will not be met, increasing pressure is now being put on coronavirus research to produce some results - and fast. In the last 48 hours, 3 of the big names studying the virus have published their latest clinical protocol to ease some of the general anxiety. Pfizer, Moderna, and AstraZeneca have all released an insight into their late-stage clinical trials that should produce data in the next few months.


While no end date has been confirmed (though sometime in October has been speculated), Pfizer’s phase 3 clinical trials are some of the fastest growing in clinical research today. According to their most recent statement, the data received from these clinical trials will need to score 50% efficacy to qualify for approval by the FDA.


Moderna’s research appears to be in a similar position. The company’s announcement estimated that trials would produce workable data somewhere between the last few months of 2020 and the early days of 2021. Moderna’s ‘mRNA-1273’, subject to the success of an interim analysis, will continue to be assessed under blind conditions to clarify the substance’s long-term safety and efficacy. As of today, 25,000 patients have been enrolled into the pharma’s clinical trials, with around half now being administered a second shot of the compound.


Due to stop and starts over the last few months, AstraZeneca was the last to publish updates on their progress. According to the company’s statement, their ‘AZD1222’ compound is planning to undergo only one interim analysis that could, if successful, see the product ready for use in early next year. Despite this optimism, however, there still remains concerns surrounding the efficacy of their drug; as only a few weeks ago phase 3 clinical trials were halted due to serious safety concerns arising in one of the study’s patients. The company’s UK trials have now recommenced - but their US operations remain at a standstill.



Here at Citruslabs, we are dedicated to keeping you up-to-date on the latest clinical trial news. With the success of our #1 health app, Mindmate, and our industry-leading patient recruitment dashboard, Citrus, we know a thing or two about clinical research. Check out our archives for all our top tips and tricks on running successful clinical trials in today's constantly changing industry.


Introducing Citrus


Research sites looking to increase patient recruitment and retention in clinical trials should look no further than Citrus. Our patient recruitment dashboard provides your study with fully integratable software to streamline your patient recruitment process. Recruit at scale with a human touch through automated, customized campaigns, and engage your patients in ways not possible with CTMS systems.


With over 200 research sites using the Citrus platform to screen thousands of patients every month, researchers across the globe are getting one step closer to finding new treatments for hundreds of different health conditions. Save valuable hours in your recruitment timeline. Increase on-site screenings, boost your enrollment targets, and retain more patients in your clinical trials.



Clinical trials run on Citrus.


Still a little unsure? Check out what our customers have to say about us here.


Citruslabs

Copyright © 2020

All rights reserved

MindMate Inc.

Company

Product

Support

  • LinkedIn
  • Twitter
  • Instagram

1639 11th Street, Suite B-208, Santa Monica, CA 90404